SCHEMBL23212064

SCHEMBL23212064

O=C(O)N1CCC(c2ccc(OC(F)(F)F)cc2)C1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52
EPHX2 P34913 9/20 0.50
F2R P25116 3/20 0.49
FAAH O00519 1/20 0.49
ALDH1A1 P00352 3/20 0.48
RAB9A P51151 3/20 0.48
GAA P10253 2/20 0.48
MAPT P10636 2/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
HSD11B1 P28845 1/20 0.46
CYP2C9 P11712 3/20 0.45
CYP2C19 P33261 2/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
HTT P42858 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
EPHX1 P07099 1/20 0.45
MGLL Q99685 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23211936 0.84 NOTUM (0.52) MEN1KMT2AFAAHRAB9AMAPT
SCHEMBL21381632 0.84 NOTUM (0.52) MEN1KMT2AFAAHRAB9AMAPT
SCHEMBL23211941 0.83 GPR119 (0.56) MEN1KMT2AEPHX2FAAHALDH1A1
SCHEMBL22944171 0.81 MEN1 (0.53) MEN1KMT2AEPHX2F2RFAAH
SCHEMBL2937123 0.79 RAB9A (0.67) FAAHALDH1A1RAB9AGAAMAPT
SCHEMBL2937126 0.79 RAB9A (0.67) FAAHALDH1A1RAB9AGAAMAPT
SCHEMBL17130352 0.78 EPHX2 (0.63) EPHX2FAAHEPHX1
SCHEMBL21381950 0.78 MEN1 (0.45) MEN1KMT2AEPHX2F2RFAAH
Bicarbonate SCHEMBL9630044 0.78 EPHX2 (0.52) MEN1KMT2AEPHX2FAAHALDH1A1
SCHEMBL4183397 0.77 GPR119 (0.61) EPHX2FAAHALDH1A1MAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230117324-A1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2023-04-20 US disclosed
EP-3768684-B1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS HOFFMANN LA ROCHE (CH) 2023-02-22 EP disclosed
US-20210107920-A1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2021-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210107920-A1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS MGLL, LPL, LIPC MEN1 1218/4885KMT2A 2681/4885EPHX2 402/4885
US-20230117324-A1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS MGLL, LPL, LIPC MEN1 1218/4885KMT2A 2681/4885EPHX2 402/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.